Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 8/20 | 0.42 |
| ▸ | HTR2B | P41595 | 6/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | LATS1 | O95835 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2155124 | 1.00 | RAD52 (0.46) | RAD52HTR2CHTR2BHTR6SLC6A2 | |
| SCHEMBL5633055 | 1.00 | RAD52 (0.46) | RAD52HTR2CHTR2BHTR6SLC6A2 | |
| Hydrochloric Acid SCHEMBL5635921 | 0.98 | RAD52 (0.48) | RAD52HTR2CHTR2BHTR6SLC6A2 | |
| Hydrochloric Acid SCHEMBL5633670 | 0.98 | RAD52 (0.48) | RAD52HTR2CHTR2BHTR6SLC6A2 | |
| Hydrochloric Acid SCHEMBL5633665 | 0.98 | RAD52 (0.48) | RAD52HTR2CHTR2BHTR6SLC6A2 | |
| SCHEMBL22542020 | 0.84 | ADRB1 (0.52) | RAD52HTR2CHTR2BHTR6SLC6A2 | |
| SCHEMBL22542046 | 0.84 | ADRB1 (0.52) | RAD52HTR2CHTR2BHTR6SLC6A2 | |
| SCHEMBL4025392 | 0.84 | ADRB1 (0.52) | RAD52HTR2CHTR2BHTR6SLC6A2 | |
| SCHEMBL22411659 | 0.83 | RAD52 (0.49) | RAD52HTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL748619 | 0.83 | RAD52 (0.43) | RAD52HTR2CHTR2BHTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | claimed |
| CN-1809545-A | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5HT2c | ARENA PHARM INC (US) | 2006-07-26 | — | — | CN | claimed |
| US-20210052600-A1 | THERAPEUTIC AGENTS FOR STRESS URINARY INCONTINENCE AND INCOTINENCE OF FECES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-25 | — | — | US | disclosed |
| EP-3733204-A1 | THERAPEUTIC AGENT FOR STRESS URINARY INCONTINENCE AND FECAL INCONTINENCE | Takeda Pharmaceutical Company Limited (JP) | 2020-11-04 | — | — | EP | disclosed |
| EP-2938344-B1 | PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME (US) | 2017-06-21 | — | — | EP | disclosed |
| US-9676780-B2 | Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676780-B2 | Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160194330-A1 | PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160194330-A1 | PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | US | disclosed |
| WO-2014105664-A1 | PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2014-07-03 | — | — | WO | disclosed |
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| CN-1809545-A | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5HT2c | ARENA PHARM INC (US) | 2006-07-26 | — | — | CN | disclosed |
| EP-1644347-A1 | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT sb 2C /sb RECEPTOR ASSOCIATED DISEASES | Arena Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005016902-A1 | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194330-A1 | PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | ADORA2A, ADORA1, ADORA3 | RAD52 3285/4885HTR2C 13/4885HTR2B 42/4885 |
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | HTR2C, HTR2A, HTR5A | RAD52 1733/4885HTR2C 1/4885HTR2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.